Bai 2007.

Methods	Allocation: randomised, no further detail. Blindness: unclear. Duration: twelve weeks. Design: parallel. Setting: inpatient, China.
Participants	Diagnosis: schizophrenia (CCMD‐3). PANSS of 60 or more. N = 118. Age: 20～50 years, aripiprazole group, mean = (32 ± 11) years; clozapine group, mean= (32 ± 13) years. Gender: aripiprazole group: 34 male, 25 female; clozapine group: 38 male, 21 female. History: aripiprazole group: 1～36 months, mean = (22 ± 5) months; clozapine group: 1～36 months, mean = (20 ± 7) months. Age at onset not reported.
Interventions	1. Aripiprazole: Dose range: 5‐30 mg/day. Mean = (20 ± 5) mg/day. N = 59. 2. Clozapine: Dose range: 50‐650 mg/day. Mean dose: (450 ± 125) mg/day. N = 59.
Outcomes	Global state: PANSS score decreased rate (markedly improved: > 60%, improved: 40%‐60%, no effect: < 25%). Mental state: PANSS total score, PANSS positive subscale score, PANSS negative subscale score. Adverse events. Unable to use: Mental state: PANSS anxiety subscale score ‐ unvalidated subscale. Cognitive functioning: PANSS cognitive factor subscale score ‐ unvalidated subscale.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further details.
Allocation concealment (selection bias)	Unclear risk	Not reported.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Unclear.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Unclear if outcome was assessed blindly.
Incomplete outcome data (attrition bias) All outcomes	Low risk	No incomplete data.
Selective reporting (reporting bias)	High risk	The outcome did not include missing data. There were no data on other adverse events. This procedure may have missed important data.
Other bias	Low risk	None obvious.